[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Although various therapies have been tried to improve advanced nonresectable pancreatic cancer, a sufficient consensus has not yet been obtained about the treatment. We have performed arterial infusion chemotherapy for pancreatic cancer in order to maintain QOL. The response rate was 17.3%, the mean survival time 282.1+/-204.7 days, median survival time 243.0+/-84.7 days, and many patients were continuously treated on an outpatient basis. It is thus expected that survival time and maintenance of QOL can be extended by self-sustaining arterial infusion chemotherapy.
Suga
Hideya
H
Division of Gastroenterology, Dept. of Medicine, Kurume University School of Medicine.
Okabe
Yoshinobu
Y
Ono
Naofumi
N
Saito
Fumihiko
F
Nagaoka
Sakae
S
Tsuruta
Osamu
O
Toyonaga
Atsushi
A
Sata
Michio
M
D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002445:Celiac Artery / Q000000981:diagnostic imaging; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D017538:Mesenteric Artery, Superior / Q000000981:diagnostic imaging; D016685:Mitomycin / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011788:Quality of Life; D011859:Radiography; D015996:Survival Rate; D000093542:Gemcitabine
D003841:Deoxycytidine; D015251:Epirubicin; D016685:Mitomycin; D005472:Fluorouracil; D000093542:Gemcitabine